[Topical aspects of etiopathogenesis, medicamentous and laser treatment of branch retinal vein occlusion].
In this review, etiopathology and non-surgical management of branch retinal vein occlusion (BRVO) are considered. To date, retinal laser photocoagulation is the only therapeutic modality proven to be efficient in the treatment of BRVO complications. Although intravitreal injections of inhibitors of the vascular endothelial growth factor and triamcinolone acetonide appear to be the most promising tools for the reduction of persistent macular edema and neovascular retinal complications, they are still prescribed for off-label applications. The use of isovolemic hemodilution and intravitreal injections of fibrinolytics is limited in patients with BRVO and does not resolve the main problem, i.e. elimination of vein occlusion. Other medicamentous modalities proposed for the management of BRVO proved inefficient. In conclusion, further studies are needed to develop new methods for the treatment of BRVO.
Toropygin
S G
SG
Moshetova
L K
LK
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D003937:Diagnosis, Differential; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005451:Fluorescein Angiography / Q000379:methods; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D005343:Fibrinolytic Agents; D005938:Glucocorticoids